| MAILLOT, François |
| Recruiting | N/A | 225 | Europe | Sampling | University Hospital, Tours | Vasculitis | 12/37 | 12/37 | | |
MATAC, NCT06444477: Molecular Analysis of Thrombocytopenia and Cancer (): Investigating Antigenic Mimicry Between Platelets and Tumor Cells in Patients With Immune Thrombocytopenia (ITP) Associated With Cancer |
|
|
| Not yet recruiting | N/A | 70 | Europe | ITP and cancer | University Hospital, Bordeaux | Immune Thrombocytopenia, Immune Thrombocytopenic Purpura, Neoplasms, Cancer | 12/24 | 12/24 | | |
| Recruiting | N/A | 350 | Europe | Blood samples, Tracheal Aspirates, Surplus of Broncho-alveolar lavage fluid | University Hospital, Tours | Community-acquired Pneumonia, Acute Respiratory Distress Syndrome, Innate Immunity | 09/24 | 03/25 | | |
| MARCHAND-ADAM, Sylvain |
| Recruiting | 4 | 378 | Europe | pirfenidone and nintedanib, pirfenidone or nintedanib | Hospices Civils de Lyon, Ministry of Health | Progressive Idiopathic Pulmonary Fibrosis | 01/26 | 01/26 | | |
| Terminated | 3 | 372 | Europe, US, RoW | Pamrevlumab, FG-3019, Placebo | FibroGen | Idiopathic Pulmonary Fibrosis | 09/23 | 09/23 | | |
|
| Completed | 3 | 397 | Europe, Canada, Japan, US, RoW | GSK3511294, Depemokimab, Placebo | GlaxoSmithKline, Iqvia Pty Ltd | Asthma | 04/24 | 04/24 | | |
|
| Active, not recruiting | 3 | 1667 | Europe, Canada, Japan, US, RoW | GSK3511294 (Depemokimab), Mepolizumab, Benralizumab, Placebo, Standard of care (SoC), Pre-filled Syringes (PFS) | GlaxoSmithKline, Iqvia Pty Ltd | Asthma | 10/25 | 10/25 | | |
|
EvER-ILD2, NCT05596786: Evaluation of Efficacy and Safety of Rituximab in Patients With Progressive Interstitial Lung Disease (ILD) With Inflammatory Component: a Multicentre Double-blind Placebo-controlled Randomized Trial |
|
|
| Recruiting | 3 | 126 | Europe | Rituximab, Placebo | University Hospital, Tours | Lung Diseases | 07/26 | 07/26 | | |
EXPOSOMFPI, NCT04619199: Influence of Socioeconomic and Environmental Factors on the Natural History of Idiopathic Pulmonary Fibrosis |
|
|
| Recruiting | N/A | 200 | Europe | Blood sample | Assistance Publique - Hôpitaux de Paris, Institut National de la Santé Et de la Recherche Médicale, France | Idiopathic Pulmonary Fibrosis, Pulmonary Disease, Pulmonary Medicine | 04/22 | 04/25 | | |
| Completed | N/A | 19 | Europe | 24h urine, urine sample | University Hospital, Tours | Lymphangioleiomyomatosis, Tuberous Sclerosis Complex | 10/22 | 10/22 | | |
| Recruiting | N/A | 350 | Europe | Blood samples, Tracheal Aspirates, Surplus of Broncho-alveolar lavage fluid | University Hospital, Tours | Community-acquired Pneumonia, Acute Respiratory Distress Syndrome, Innate Immunity | 09/24 | 03/25 | | |
| MANKIKIAN, Julie Julie |
| Recruiting | 3 | 270 | Europe | Placebos, Dobutamine | University Hospital, Limoges, Centre d'Investigation Clinique 1415 | Sepsis, Cardiomyopathies, Hypoperfusion, Left Ventricular Systolic Dysfunction | 12/25 | 12/25 | | |
| Active, not recruiting | 3 | 597 | Europe, RoW | Placebo, Inhaled Treprostinil, Tyvaso, Treprostinil Ultrasonic Nebulizer | United Therapeutics | Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease | 07/25 | 07/25 | | |
| Recruiting | N/A | 350 | Europe | Blood samples, Tracheal Aspirates, Surplus of Broncho-alveolar lavage fluid | University Hospital, Tours | Community-acquired Pneumonia, Acute Respiratory Distress Syndrome, Innate Immunity | 09/24 | 03/25 | | |
DIAPASOM, NCT06457451: Impact of a Coordinated Dietetic-adapted Physical Activity Program on the Percentage of Lean Body Mass in Adults With Cystic Fibrosis Treated With Elexacaftor-Tezacaftor-Ivacaftor: Multicentre Randomised Controlled Trial |
|
|
| Recruiting | N/A | 100 | Europe | DIAPASOM program | University Hospital, Tours, Fondation Ildys | Cystic Fibrosis | 11/27 | 11/27 | | |
| FLAMENT, Thomas |
EXAFIP2, NCT05674994: Glucocorticoids Versus Placebo for the Treatment of Acute Exacerbation of Idiopathic Pulmonary Fibrosis |
|
|
| Recruiting | 3 | 110 | Europe | Methylprednisone/Prednisone, Placebo | Fondation Hôpital Saint-Joseph | Acute Exacerbation of Idiopathic Pulmonary Fibrosis | 10/25 | 12/26 | | |
| Recruiting | N/A | 350 | Europe | Blood samples, Tracheal Aspirates, Surplus of Broncho-alveolar lavage fluid | University Hospital, Tours | Community-acquired Pneumonia, Acute Respiratory Distress Syndrome, Innate Immunity | 09/24 | 03/25 | | |
| BIGOT, Adrien |
| Completed | 3 | 157 | Europe, Canada, US, RoW | PTC923, Placebo | PTC Therapeutics | Phenylketonuria | 04/23 | 05/23 | | |
| Recruiting | 3 | 200 | Europe, Canada, Japan, US, RoW | PTC923, Sepiapterin | PTC Therapeutics | Phenylketonuria | 04/26 | 04/26 | | |
| Recruiting | N/A | 350 | Europe | Blood samples, Tracheal Aspirates, Surplus of Broncho-alveolar lavage fluid | University Hospital, Tours | Community-acquired Pneumonia, Acute Respiratory Distress Syndrome, Innate Immunity | 09/24 | 03/25 | | |
| Carmier, Delphine |
COSTAR Lung, NCT04655976 / 2020-003433-37: Efficacy Comparison of Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in Participants With Advanced Non-small Cell Lung Cancer Who Have Progressed on Prior Anti-PD-(L)1 Therapy and Chemotherapy |
|
|
| Active, not recruiting | 3 | 758 | Europe, Canada, Japan, US, RoW | Cobolimab, Dostarlimab, Docetaxel | GlaxoSmithKline | Lung Cancer, Non-Small Cell | 04/25 | 10/25 | | |
ORBITAL, NCT04233021: Study of Osimertinib in Patients with a Lung Cancer with Brain or Leptomeningeal Metastases with EGFR Mutation |
|
|
| Completed | 2 | 57 | Europe | Osimertinib | Intergroupe Francophone de Cancerologie Thoracique | Non Small Cell Lung Cancer Metastatic, Leptomeningeal Metastasis, Brain Metastases, EGFR Activating Mutation | 03/23 | 12/24 | | |
| Active, not recruiting | 2 | 50 | Europe | Durvalumab | Intergroupe Francophone de Cancerologie Thoracique, IFCT, AstraZeneca | Non-small Cell Lung Cancer Stage IV | 11/23 | 10/25 | | |
| Recruiting | 2 | 119 | Europe | Encorafenib 75 MG, Binimetinib 15 MG | Intergroupe Francophone de Cancerologie Thoracique, IFCT, Pierre Fabre | Non Small Cell Lung Cancer, BRAF V600E | 12/24 | 03/26 | | |
|
SPORADIC, NCT06656598: Study Evaluating the Efficacy and the Tolerance of Immunochemotherapy and Sequential Hypofractionated Radiotherapy in Unfit or Elderly Patients with Stage III Lung Cancer |
|
|
| Not yet recruiting | 2 | 152 | Europe | Carboplatin, Paclitaxel, Cemiplimab, Curative hypofractionated radiotherapy, Cemiplimab (maintenance) | Intergroupe Francophone de Cancerologie Thoracique | Stage III NSCLC | 09/28 | 01/32 | | |
NCT04621188: Lorlatinib After Failure of First-line TKI in Patients with Advanced ROS1-positive NSCLC (ALBATROS) |
|
|
| Recruiting | 2 | 84 | Europe | Lorlatinib | Intergroupe Francophone de Cancerologie Thoracique | Non Small Cell Lung Cancer Metastatic | 03/25 | 01/26 | | |
ADAPTABLE, NCT05781308: Combination of Paclitaxel-bevacizumab ± Atezolizumab in Patients with Advanced NSCLC Progressing After Immunotherapy & Chemotherapy |
|
|
| Active, not recruiting | 2 | 156 | Europe | Paclitaxel, Bevacizumab, Avastin, Atezolizumab, Tecentriq | Intergroupe Francophone de Cancerologie Thoracique | Non Small Cell Lung Cancer | 09/25 | 06/26 | | |
| Recruiting | N/A | 350 | Europe | Blood samples, Tracheal Aspirates, Surplus of Broncho-alveolar lavage fluid | University Hospital, Tours | Community-acquired Pneumonia, Acute Respiratory Distress Syndrome, Innate Immunity | 09/24 | 03/25 | | |
ROSIE, NCT06053099: A Prospective Cohort Study to Evaluate Molecular pRognostic Factors and Resistance Mechanisms to Osimertinib in Adjuvant Treatment of Completely Resected pIB-IIIA Non-small Cell Lung Carcinoma With Common EGFR Mutations (L858R and Del19) |
|
|
| Recruiting | N/A | 300 | Europe | Plasma ctDNA, FFPE blocks | Intergroupe Francophone de Cancerologie Thoracique | Non Small Cell Lung Cancer, EGFR Activating Mutation, EGFR DEL19, EGFR L858R | 10/31 | 10/31 | | |
| AUDEMARD-VERGER, Alexandra |
| Recruiting | N/A | 350 | Europe | Blood samples, Tracheal Aspirates, Surplus of Broncho-alveolar lavage fluid | University Hospital, Tours | Community-acquired Pneumonia, Acute Respiratory Distress Syndrome, Innate Immunity | 09/24 | 03/25 | | |
